Insulet Presents Next Gen Omnipod Innovations To Reduce User Effort, New Algorithm Data, And Clinical Evidence Demonstrating Improved Time In Range During ADA 86th Scientific Sessions

Insulet Corporation

Insulet Corporation

PODD

0.00
  • Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range
  • Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.